ANG4043 / Angiochem - LARVOL DELTA

Angiochem publishes data on ANG4043, a brain-penetrant anti-HER2 monoclonal antibody for treatment of brain metastases (Businesswire) - "In vivo, ANG4043 achieves therapeutic brain concentrations in healthy mice and in mice bearing intracranial HER2+ tumors, which are targeted by ANG4043. In this HER2+ intracranial tumor model, treatment with ANG4043 (15 mg/kg IV, twice-weekly) increased median survival time by 78% (80 days compared to 45 days for control)."

Preclinical • Oncology